In February 2019, EU Directive 2011/62/EU against counterfeit medicines came into force, specifying that prescription medicines may only be sold if they are marked with two specific safety features. This ensures that each package can be clearly identified and thus prevents the issue of counterfeits. The directive aims to protect patients from counterfeit medicines within the legal supply chain.

The fact that, in addition to Spain, other EU countries such as Germany, France, Portugal, and Norway also rely on Arvato Systems as an implementation partner, and that Spain is now extending the contractual relationship, demonstrates the quality of Arvato Systems‘ national verification system.

"We are delighted that Spain continues to rely on the services of our national verification system. Together we can continue to develop the system and adapt it to the latest standards. We look forward to further cooperation with great pleasure," says Stefan Moch, Vice President Health at Arvato Systems.

The implementation of the IT solution in Spain is characterized by the fact that Spain is the only country that operates the national verification system on-site and thus meets the requirements of the Spanish authorities. Arvato Systems remains responsible for project management and customer care as well as technical support.